Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease

Gastroenterology

Volumn 143, Issue 6, 2012, Pages 1461-1469

  D'Haens, Geert ^a   Feagan, Brian ^b   Colombel, Jean Frédéric ^c   Sandborn, William J ^d   Reinisch, Walter ^e   Rutgeerts, Paul ^f   Carbonnel, Frank ^g   Mary, Jean Yves ^h   Danese, Silvio ⁱ   Fedorak, Richard N ^j   Hanauer, Steven ^k   Lémann, Marc ^l  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h INSERM   (France)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j UNIVERSITY OF ALBERTA   (Canada)

^k UNIVERSITY OF CHICAGO   (United States)

^l SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Clinical Trials; Crohn's Disease; Inflammatory Bowel Disease; Trial Design; Ulcerative Colitis

Indexed keywords

ABATACEPT; ALICAFORSEN; BASILIXIMAB; BRIAKINUMAB; C REACTIVE PROTEIN; DACLIZUMAB; ETANERCEPT; FONTOLIZUMAB; GROWTH HORMONE; ONERCEPT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; VISILIZUMAB;

ARTICLE; COLONOSCOPY; DISEASE COURSE; DRUG EFFICACY; ENTERITIS; HEALING; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

EID: 84869846163     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.09.031     Document Type: Review

References (58)

1. G. D'Haens, R. Fedorak, M. Lémann Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease Inflamm Bowel Dis 15 2009 1599 1604
2. Guideline on the development of new medicinal products for the treatment of Crohn's disease http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003214.pdf
3. W.J. Sandborn, R. Löfberg, B.G. Feagan Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials Am J Gastroenterol 100 2005 1780 1787
4. S.P. Travis, E.F. Stange, M. Lémann European Crohn's and Colitis Organisation European evidence-based Consensus on the management of ulcerative colitis: current management J Crohns Colitis 2 2008 24 62
5. A.C. Ford, S.V. Kane, K.J. Khan Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 617 629
6. W.J. Sandborn, B.G. Feagan, S.B. Hanauer A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease Gastroenterology 122 2002 512 530
7. B.L. Wiens Choosing an equivalence limit for noninferiority or equivalence studies Control Clin Trials 23 2002 2 14
8. G. D'Haens, W.J. Sandborn, K. Barrett Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis Am J Gastroenterol 107 2012 1064 1077
9. W.J. Sandborn, J. Korzenik, B. Lashner Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis Gastroenterology 138 2010 1286 1296
10. G. Van Assche, A. Dignass, J. Panes European Crohn's and Colitis Organisation The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis J Crohns Colitis 4 2010 7 27
11. J.Y. Mary, R. Modigliani Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study Gut 30 1989 983 989
12. J. Rimola, S. Rodriguez, O. García-Bosch Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease Gut 58 2009 1113 1120
13. Feagan BJ, Sandborn WJ, D'Haens G, et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC) (abstr). Presented at: ACG 2012 Annual Scientific Meeting; October 19-24, 2012; Las Vegas, NV.
14. W.J. Sandborn, S. Ghosh, J. Panes Phase 2 study of tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in active Crohn's disease Gastroenterology 140 Suppl 1 2011 745
15. T.A. Yousry, E.O. Major, C. Ryschkewitsch Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 2006 924 933
16. C. Ha, T.A. Ullman, C.A. Siegel Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population Clin Gastroenterol Hepatol 10 2012 1002 1007
17. G.R. Greenberg, B.G. Feagan, F. Martin et al. Oral budesonide for active Crohn's disease Canadian Inflammatory Bowel Disease Study Group N Engl J Med 331 1994 836 841
18. J.K. Marshall, M. Thabane, A.H. Steinhart Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 1 2010 CD004115
19. B.E. Sands, F.H. Anderson, C.N. Bernstein Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885
20. S.B. Hanauer, B.I. Korelitz, P. Rutgeerts Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial Gastroenterology 127 2004 723 729
21. K.F. Froslie, J. Jahnsen, B.A. Moum Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort Gastroenterology 133 2007 412 422
22. G. D'Haens, W.J. Sandborn, B.G. Feagan A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
23. J.F. Colombel, W.J. Sandborn, W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
24. R. Panaccione, S. Ghosh, S. Middleton Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial J Crohns Colitis 6 2012 (abstract)
25. A. Donner, N. Birkett, C. Buck Randomization by cluster Sample size requirements and analysis Am J Epidemiol 114 1981 906 914
26. P. Rutgeerts, G. D'Haens, G. Van Assche Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease-first results of the EXTEND trial Gastroenterology 142 2012 1102 1111
27. W.R. Best, J.M. Becktel, J.W. Singleton Development of a Crohn's Disease Activity Index Gastroenterology 70 1976 439 444
28. K.T. Thia, W.J. Sandborn, J.D. Lewis Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease Am J Gastroenterol 103 2008 3123 3131
29. R.F. Harvey, J.M. Bradshaw A simple index of Crohn's-disease activity Lancet 1 1980 514
30. S. Vermeire, S. Schreiber, W.J. Sandborn Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity Clin Gastroenterol Hepatol 8 2010 357 363
31. W. Afif, E.V. Loftus Jr, W.A. Faubion Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease Am J Gastroenterol 105 2010 1133 1139
32. P. Rutgeerts, R.H. Diamond, M. Bala Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 126 2004 402 413
33. B. Turnbull The empirical distribution function with arbitrarily grouped, censored and truncated data J R Stat Soc B 38 1976 290 295
34. K.W. Schroeder, W.J. Tremaine, D.M. Ilstrup Coated oral aminosalicylic acid therapy for mildly to moderately active ulcerative colitis N Engl J Med 317 1987 1625 1629
35. S. Lichtiger, D.H. Present, A. Kornbluth Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845
36. G. D'Haens, L. Lemmens, K. Geboes Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis: a double-blind controlled randomised trial Gastroenterology 120 2001 1323 1329
37. D. Laharie, A. Bourreille, J. Branche Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial Lancet 2012 October 9 [Epub ahead of print]
38. W.J. Sandborn, J.F. Colombel, M. Frankel Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis Gut 59 2010 1485 1492
39. D.C. Baumgart, S.R. Targan, A.U. Dignass Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis Inflamm Bowel Dis 16 2010 620 629
40. J. Langhorst, S. Elsenbruch, J. Koelzer Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices Am J Gastroenterol 103 2008 162 169
41. T. Sipponen, E. Savilahti, K.L. Kolho Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings Inflamm Bowel Dis 14 2008 40 46
42. P.F. van Rheenen, E. Van de Vijver, V. Fidler Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis BMJ 341 2010 c3369
43. G. D'Haens, M. Ferrante, S. Vermeire Faecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseases Inflamm Bowel Dis 2012 Feb 16 [Epub ahead of print]
44. J.Y. Mary, R. Modigliani GETAID Development and validation of an endoscopic index of severity for Crohn's disease: a prospective multicenter study Gut 30 1989 983 989
45. M. Daperno, G.R. D'Haens, G. Van Assche Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD Gastrointest Endosc 60 2004 505 512
46. P. Rutgeerts, K. Geboes, G. Vantrappen Predictability of the postoperative course of Crohn's disease Gastroenterology 99 1990 956 963
47. X. Hébuterne, J. Colombel, Y. Bouhnik Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol Gut 2012 Jun 19 [Epub ahead of print]
48. M. Ferrante, J.F. Colombel, W.J. Sandborn Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post-hoc analysis of the SONIC data (abstr) Gastroenterology 140 2011 S909
49. J.H. Baron, A.M. Connell, T.G. Kanaghinis Out-patient treatment of ulcerative colitis Comparison between three doses of oral prednisone Br Med J 2 1962 441 443
50. S.P. Travis, D. Schnell, P. Krzeski Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Gut 61 2012 535 542
51. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial Lancet 359 2002 1541 1549
52. S. Schreiber, M. Khaliq-Kareemi, I.C. Lawrance Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 2007 239 250
53. J.F. Colombel, W.J. Sandborn, P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65
54. W.J. Sandborn, B.G. Feagan, S. Stoinov Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238
55. Guideline on the development of new medicinal products for the treatment of Crohn's disease http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003214.pdf
56. B. Pariente, J. Cosnes, S. Danese Development of the Crohn's disease digestive damage score, the Lémann score Inflamm Bowel Dis 17 2011 1415 1422
57. A. Ilnyckyj, F. Shanahan, P.A. Anton Quantification of the placebo response in ulcerative colitis Gastroenterology 112 1997 1854 1858
58. C. Su, G.R. Lichtenstein, K. Krok A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease Gastroenterology 126 2004 1257 1269